Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acarbose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY2A known ✓ | P04746 | 9/20 | 1.00 |
| ▸ | MGAM known ✓ | O43451 | 6/20 | 1.00 |
| ▸ | SI | P14410 | 5/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | TREH | O43280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acarbose SCHEMBL19736300 | 1.00 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL611277 | 1.00 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL9929862 | 1.00 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL22252575 | 1.00 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL22252576 | 1.00 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A | |
| SCHEMBL14409049 | 1.00 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL4068725 | 1.00 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL14223718 | 1.00 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL22651301 | 1.00 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A | |
| Acarbose SCHEMBL16204157 | 1.00 | AMY2A (1.00) | AMY2AMGAMSIGAAAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016786-A1 | GLUCOSIDASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PULMONARY INFECTIONS | COVIRIX Medical Pty Ltd (AU) | 2024-01-18 | — | — | US | disclosed |
| US-20240016786-A1 | GLUCOSIDASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PULMONARY INFECTIONS | COVIRIX Medical Pty Ltd (AU) | 2024-01-18 | — | — | US | disclosed |
| US-9402925-B2 | Probes and methods of imaging a bacterial infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (US) | 2016-08-02 | — | — | US | disclosed |
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-8017633-B2 | Administering [3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide; hypertension, hyperlipidemia, hyperuricemia, gout and hypercoagulability | NYCOMED GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20110177026-A1 | Use of Alpha-Glucosidase Inhibitors to Treat Alphavirus Infections | INTERMUNE, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7932267-B2 | Use of α-glucosidase inhibitors to treat alphavirus infections | INTERMUNE, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100150867-A1 | USE OF ALPHA-GLUCOSIDASE INHIBITORS TO TREAT ALPHAVIRUS INFECTIONS | INTERMUNE, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7638488-B2 | Use of alpha-glucosidase inhibitors to treat alphavirus infections | INTERMUNE, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638488-B2 | Use of alpha-glucosidase inhibitors to treat alphavirus infections | INTERMUNE, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | KONINKLIJKE HILIPS ELECTRONICS, N.V. (NL) | 2008-09-04 | — | — | US | disclosed |
| US-7271158-B2 | Treatment of rumen acidosis with α-amylase inhibitors | PFIZER INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271158-B2 | Treatment of rumen acidosis with α-amylase inhibitors | PFIZER INC. (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | GPR119, IAPP, MTNR1B | AMY2A 15/4885MGAM 530/4885SI 1011/4885 |
| US-20240016786-A1 | GLUCOSIDASE INHIBITORS FOR THE TREATMENT AND PREVENTION OF PULMONARY INFECTIONS | ACE2, GAA, GBA3 | AMY2A 102/4885MGAM 6/4885SI 44/4885 |
| US-20110177026-A1 | Use of Alpha-Glucosidase Inhibitors to Treat Alphavirus Infections | GBA3, GAA, GANAB | AMY2A 57/4885MGAM 14/4885SI 41/4885 |
| US-20100150867-A1 | USE OF ALPHA-GLUCOSIDASE INHIBITORS TO TREAT ALPHAVIRUS INFECTIONS | GBA3, GAA, GANAB | AMY2A 57/4885MGAM 14/4885SI 41/4885 |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | NOS3, PLAT, PTGIS | AMY2A 501/4885MGAM 256/4885SI 755/4885 |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | AMY2A 872/4885MGAM 930/4885SI 2468/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | AMY2A 38/4885MGAM 798/4885SI 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.